Wednesday, September 16, 2009
Tuesday, September 15, 2009
Don't say you weren't warned
"TARGETS REACHED, AND TURNS IMMINENT IN FOUR KEY MARKETS"
That is the headline of today's issue of The Elliott Wave Theorist. I have suggested this $20/month publication on this blog before and the content of today's issue is why: It contains a year's worth of subscription cost ($240) in it's ten prescient pages. I know many of you have already subscribed, and for those who haven't, you can have this issue in your hands in about 15 minutes by hitting one of the links on my site. What follows are my charts which pretty much confirm Prechter's forecast in the issue. He actually has reasons, I just have charts.
The above chart is the Daily DJIA. I've annotated the divergence in the Elliott Oscillator on the bottom of the chart and the new high this week in the index. The auto-regression channels that have contained the 5th wave to date along with the divergence on the oscillator set up what Advanced GET refers to as a Type II Mechanical Sell Signal. As long as the divergence holds, when prices break through the lower channel a SELL is triggered. That level is at about 9500 on the DJIA. Make a mental note of it, when the index drops below 9500, I suspect all hell will break loose in global financial markets. It's not that far away.
Above is the Daily SPX. Same divergence, but instead of the auto-trend channels, the Blue Wave stop/reverse SHORT level. On this Daily chart its currently at 1029.34. Same connotation applies to that level as to the above referenced 9500 level on the DJIA. Pay attention.
Above is the Daily SPX with the ATR stop/reverse level, 1025. Again, remember this level, it may not last for much longer.
Finally, the Weekly SPX chart that this site has been tracking since early March:
A triple divergence on the False Bar Stochastic, when it breaks, it will break hard and long. On the Weekly Blue Wave and ATR the key level is 984. Ditto.
If you want a head start, here is the 60 minute SPX chart with respective stop/reversal levels for Blue Wave and ATR:
Note also the deep, deep divergence in the bottom Elliott Oscillator. These two reversal SHORT levels are only about 3-5 points below current prices. Thus, here would be an aggressive first salvo for playing the next leg of the decline.
A
PS: Glenn Neely's time and price targets are coming into play right here and right now. Another relatively inexpensive way to get a heads up from an excellent analyst for those few times a year when pulling the trigger is objectively defined by his own brand of rigorous market analysis.
That is the headline of today's issue of The Elliott Wave Theorist. I have suggested this $20/month publication on this blog before and the content of today's issue is why: It contains a year's worth of subscription cost ($240) in it's ten prescient pages. I know many of you have already subscribed, and for those who haven't, you can have this issue in your hands in about 15 minutes by hitting one of the links on my site. What follows are my charts which pretty much confirm Prechter's forecast in the issue. He actually has reasons, I just have charts.
The above chart is the Daily DJIA. I've annotated the divergence in the Elliott Oscillator on the bottom of the chart and the new high this week in the index. The auto-regression channels that have contained the 5th wave to date along with the divergence on the oscillator set up what Advanced GET refers to as a Type II Mechanical Sell Signal. As long as the divergence holds, when prices break through the lower channel a SELL is triggered. That level is at about 9500 on the DJIA. Make a mental note of it, when the index drops below 9500, I suspect all hell will break loose in global financial markets. It's not that far away.
Above is the Daily SPX. Same divergence, but instead of the auto-trend channels, the Blue Wave stop/reverse SHORT level. On this Daily chart its currently at 1029.34. Same connotation applies to that level as to the above referenced 9500 level on the DJIA. Pay attention.
Above is the Daily SPX with the ATR stop/reverse level, 1025. Again, remember this level, it may not last for much longer.
Finally, the Weekly SPX chart that this site has been tracking since early March:
A triple divergence on the False Bar Stochastic, when it breaks, it will break hard and long. On the Weekly Blue Wave and ATR the key level is 984. Ditto.
If you want a head start, here is the 60 minute SPX chart with respective stop/reversal levels for Blue Wave and ATR:
Note also the deep, deep divergence in the bottom Elliott Oscillator. These two reversal SHORT levels are only about 3-5 points below current prices. Thus, here would be an aggressive first salvo for playing the next leg of the decline.
Impulsive declines don't ring bells at their inception, they just break key levels of support. These are our tools, let's use them.
A
PS: Glenn Neely's time and price targets are coming into play right here and right now. Another relatively inexpensive way to get a heads up from an excellent analyst for those few times a year when pulling the trigger is objectively defined by his own brand of rigorous market analysis.
The unbearable lightness of baskets
I added CVM to the Swine Flu basket on July 29th.
At the time, CVM had broken out above 50c and Blue Wave flagged it as an immediate BUY.
Today CVM is at $1.20.
Well done, Blue Wave.
Well done, Flu Basket.
Well done, Readers (who acted on this one).
A
At the time, CVM had broken out above 50c and Blue Wave flagged it as an immediate BUY.
Today CVM is at $1.20.
Well done, Blue Wave.
Well done, Flu Basket.
Well done, Readers (who acted on this one).
A
Monday, September 14, 2009
NNVC
NanoViricides Platform Enables Rapid Development of Robust Nanomedicines Against Influenza and HIV
Company President Dr. Diwan Describes Technology and Pipeline at NanoBusiness 2009 Conference
Press Release
Source: NanoViricides, Inc.
On Monday September 14, 2009, 9:25 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.
Dr. Diwan described the salient features of nanoviricides technology. “Viruses can be fooled,” he said, adding, “We use their own smarts to attack them. The site at which a virus binds to the cell surface never changes, no matter how much the virus itself changes. We mimic this site, and the cell surface, so the virus particle can bind to the nanoviricide thinking it is binding to a cell. We anticipate very little escape mutation problem, if we do this successfully.”
He then explained that FluCide™, was found to be as much ten to twenty times (10X to 20X or 1,000% to 2,000%) superior to oseltamivir (Tamiflu®, Roche), in lethal influenza virus challenge administered to mice. These studies have been repeated and the Company has performed SAR (structure-activity-relationship) studies to develop the best drug candidates against influenza. “Imagine the day when we will never have to develop vaccines against influenza,” he said, adding, “That’s what FluCide™ would achieve.”
He also described that HIVCide™ was found to be more than twenty-five times (25X or 2,500%) superior to the entire three drug HAART cocktail in a standard SCID-Hu mouse model study. The mice were treated with only 150 mg/kg of nanoviricides and this treatment both led to improvement in double-positive CD4+/CD8+ T cells and reduction in HIV-1 viral load that was equal to or slightly better than that in HAART-treated mice. The HAART treated mice received a total drug load of 4,200 mg/kg, indicating superior results with HIVCide. Moreover, HAART cocktail caused significant toxic effects, whereas the nanoviricides produced no clinical adverse signs in this study.
Dr. Diwan also described the high efficacy of EKCCide™ in a rabbit model, which caused complete clinical resolution of adenoviral kerato-conjunctivitis in as little as 2.5 days. The Company is not aware of any other drug candidate that had shown clinical improvement in this disease in any earlier animal studies.
Dr. Diwan also described the Social Responsibility programs of the Company, which include drug development against Dengue viruses, Rabies virus, as well as Biodefense programs that include broad-spectrum drug development against hemorrhagic viruses including Ebola/Marburg, and the ADIF™ “Accurate Drug In Field” technology against novel and emerging viruses.
“The Company has continued its development of FluCide, HIVCide, and the ocular nanoviricide eye drops, which are programs of very high commercial interest,” said Dr. Eugene Seymour, MD, MPH, commenting further that, “We continue to invest minimal amounts of Company funds in the Social Responsibility and Biodefense projects, and we will require public funding for the same.”
Press Release
Source: NanoViricides, Inc.
On Monday September 14, 2009, 9:25 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.
Dr. Diwan described the salient features of nanoviricides technology. “Viruses can be fooled,” he said, adding, “We use their own smarts to attack them. The site at which a virus binds to the cell surface never changes, no matter how much the virus itself changes. We mimic this site, and the cell surface, so the virus particle can bind to the nanoviricide thinking it is binding to a cell. We anticipate very little escape mutation problem, if we do this successfully.”
He then explained that FluCide™, was found to be as much ten to twenty times (10X to 20X or 1,000% to 2,000%) superior to oseltamivir (Tamiflu®, Roche), in lethal influenza virus challenge administered to mice. These studies have been repeated and the Company has performed SAR (structure-activity-relationship) studies to develop the best drug candidates against influenza. “Imagine the day when we will never have to develop vaccines against influenza,” he said, adding, “That’s what FluCide™ would achieve.”
He also described that HIVCide™ was found to be more than twenty-five times (25X or 2,500%) superior to the entire three drug HAART cocktail in a standard SCID-Hu mouse model study. The mice were treated with only 150 mg/kg of nanoviricides and this treatment both led to improvement in double-positive CD4+/CD8+ T cells and reduction in HIV-1 viral load that was equal to or slightly better than that in HAART-treated mice. The HAART treated mice received a total drug load of 4,200 mg/kg, indicating superior results with HIVCide. Moreover, HAART cocktail caused significant toxic effects, whereas the nanoviricides produced no clinical adverse signs in this study.
Dr. Diwan also described the high efficacy of EKCCide™ in a rabbit model, which caused complete clinical resolution of adenoviral kerato-conjunctivitis in as little as 2.5 days. The Company is not aware of any other drug candidate that had shown clinical improvement in this disease in any earlier animal studies.
Dr. Diwan also described the Social Responsibility programs of the Company, which include drug development against Dengue viruses, Rabies virus, as well as Biodefense programs that include broad-spectrum drug development against hemorrhagic viruses including Ebola/Marburg, and the ADIF™ “Accurate Drug In Field” technology against novel and emerging viruses.
“The Company has continued its development of FluCide, HIVCide, and the ocular nanoviricide eye drops, which are programs of very high commercial interest,” said Dr. Eugene Seymour, MD, MPH, commenting further that, “We continue to invest minimal amounts of Company funds in the Social Responsibility and Biodefense projects, and we will require public funding for the same.”
Saturday, September 12, 2009
Views and news
For starters, I want to provide a quick overview of the big picture seen through the weekly charts of some major averages. Time allowing later this weekend, some engaging new ideas on stock picking.
SPX Weekly
NDX Weekly
Russell 2000 Weekly
XAU Weekly
NNVC Daily
Of particular significance on above NNVC chart, a textbook cup-and-handle stretching back six months, Buy signals from both Blue Wave and ATR and bullish mode for False Bar Stochastic.
In the news.......
CORNELL STUDENT DIES OF SWINE FLU
INSIDERS SELL LIKE THERE IS NO TOMORROW
WINGS LEAVE FOR CAMP
NDX Weekly
Russell 2000 Weekly
XAU Weekly
NNVC Daily
Of particular significance on above NNVC chart, a textbook cup-and-handle stretching back six months, Buy signals from both Blue Wave and ATR and bullish mode for False Bar Stochastic.
IBPM Daily
This is a line chart of IBPM. I am using the "line" mode because this is a thinly traded stock (for now) and in from this perspective, the resistance level at 0.99 can be clearly seen.
iBioPharma has a market cap of about $23M and is in the right place at the right time:
This is a line chart of IBPM. I am using the "line" mode because this is a thinly traded stock (for now) and in from this perspective, the resistance level at 0.99 can be clearly seen.
iBioPharma has a market cap of about $23M and is in the right place at the right time:
iBioPharma, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary products from plants in the United States It uses and promotes the proprietary plant-based technology platform, which produces targeted proteins in plants for the development and manufacture of novel vaccines and therapeutics for use in humans, as well as for veterinary applications. The company is also developing product candidates for the biodefense market and for infectious diseases. Its preclinical stage product portfolio includes diagnostic product for pandemic avian influenza, seasonal influenza vaccine, pandemic influenza vaccine, therapeutic antibody for influenza, therapeutic vaccine for human papilloma virus, and an oral anthrax booster vaccine.
In the news.......
CORNELL STUDENT DIES OF SWINE FLU
INSIDERS SELL LIKE THERE IS NO TOMORROW
WINGS LEAVE FOR CAMP
Red Wing Pavel Datsyuk loads his luggage onto a bus in the parking lot at Joe Louis Arena.
A
Thursday, September 10, 2009
OREX
Here is a Weekly chart of OREX:
I will write more about where it came from later. If you want to get a head start, go to Growth Stocks Analytics.
A
I will write more about where it came from later. If you want to get a head start, go to Growth Stocks Analytics.
OREX hourly
A
Wednesday, September 09, 2009
How to Spot Trading Opportunities
I usually pass along special offers from my advertisers only after I have had a chance to evaluate the materials first. Then if I think it is worthwhile I will allow it to be promoted on my site. This particular resource is a 47-page eBook on spotting trading opportunities and I simply don't have time to read it right now. Since the offer is time sensitive, I am passing it along now. These folks at EWI do good work, my guess is that this eBook is a worthwhile download & read. As usual, all they are asking for in return is a valid email address via membership in "Club EWI." Just do it.
A
Elliott Wave International has just released a free 47-Page eBook, How to Spot Trading Opportunities. Created from the $129 two-volume set of the same name, it’s available free until September 23, 2009. Learn more.
Tuesday, September 08, 2009
Bear Being Bullish
Here is a ninety minute chart with Blue Wave signals embedded:
Now the ATR chart:
Make no mistake, I am waiting for and anticipating the floor falling out from underneath this market. But the trend never lies. With both of these systems, it looks like it will take another 8-10 points lower, beneath Tuesday's closing SPX, to trigger a Sell.
Speaking of bears being bullish:
How A Bear Can Be Bullish And Still Be Right
Bob Prechter: the only good label is an Elliott wave label...
September 8, 2009 (click to read)
A
Now the ATR chart:
Make no mistake, I am waiting for and anticipating the floor falling out from underneath this market. But the trend never lies. With both of these systems, it looks like it will take another 8-10 points lower, beneath Tuesday's closing SPX, to trigger a Sell.
Speaking of bears being bullish:
How A Bear Can Be Bullish And Still Be Right
Bob Prechter: the only good label is an Elliott wave label...
September 8, 2009 (click to read)
A
NanoViricides
Sometimes you have to read between the lines in order to recognize an emerging opportunity with enough clarity to make a calculated speculation. It is contained in the press release issued this morning by NanoViricides. More comment after the short text of the release (emphasis added):
--------------------------------------------------------------------------------------------
First of all, let's take a look at a short biography of Dr. Diwan (emphasis added):
Cutting to the chase, Dr. Diwan is the inventor of the nanomaterial that destroys viruses and we are the shareholders of the company that has exclusive rights to develop and market the technology. Dr. Diwan is talking in Chicago on Wednesday to update NNVC's pipeline.....and rapid drug development platform.
We know that there are multiple ongoing testing protocols across a wide selection of targeted viruses and being performed by private labs, big pharma, educational institutions, the CDC and the NIH. What we don't know yet is how well those tests are going and what if any findings are imminent.
What are the chances that Dr Diwan's scheduled appearance has some very good news attached to it?
This may end up being a non-event with no significant news coming out of it. Or it might be the polar opposite, with ground-breaking news making headlines across the medical universe. My best guess? Something in-between these last two outcomes. Just where it lands on the continuum between the two, that is what speculation is all about.
A
--------------------------------------------------------------------------------------------
NanoViricides, Inc. President Invited to Speak About Rapid Drug Development--------------------------------------------------------------------------------------------
Dr. Diwan to speak about rapid drug development enabled by nanoviricides™ technology at the NanoBusiness2009 Conference
On Tuesday September 8, 2009, 7:00 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been asked to present a talk at NanoBusiness2009 - the 8th annual NanoBusiness Conference.
Dr. Diwan will speak about the nanoviricides™ drug pipeline, including Influenza (FluCide™), HIV (HIVCide™), antiviral eye-drops (EKCCide™) and the newly initiated Herpes “cold sores” and genital herpes preclinical stage program. He will speak about how the nanoviricides technology platform has enabled rapid drug development against a number of diseases caused by many different viruses. Dr. Diwan will speak in the session entitled “New Pharmaceutical Compounds Based on Soft Nanotechnology: Novel Classes of Therapeutics” on Wednesday, September 9.
The Conference is being held at the McCormick Place, Chicago, IL.
About NanoBusiness2009
This is the 8th annual conference on the business of nanotechnology organized by the NanoBusiness Alliance. The NanoBusiness Alliance mission is to create a collective voice for the advancing nanotechnology industry and develop a range of initiatives to support the nanotechnology business community.
First of all, let's take a look at a short biography of Dr. Diwan (emphasis added):
Anil R. Diwan, PhD
Chairman and President
Inventor of TheraCour technology that enables NanoViricides drugs.
Dr. Diwan has extensive product development experience while raising financing from collaborations, SBIR grants, other revenues. He has extensive experience in a number of bio-pharmaceutical, biosciences, and biomedical fields and technologies that leads to his novel, integrative approach in solving problems with low costs, high innovation, and world-leading feature sets. Dr. Diwan is the inventor, developer, and principal investor of TheraCour technologies. The nanomaterials based on these technologies form the basis of nanoviricides drugs.
Anil holds a US patent on his older polymeric micelle technologies, with his colleagues at University of Massachusetts. He has continued to work further in the field, to develop nanomaterials that are capable of multi-specific multi-targeting of viruses, and at the same time capable of encapsulating active pharmaceutical ingredients (API) in industry-leading payload capacities. This new work has resulted in nanomaterials called "TheraCour" (therapeutic courier), and the underlying technology is subject of a new patent application. Multi-targeting allows binding to the virus particle like a Velcro tape, and Multi-specificity allows highly selective binding to a specific type of virus. The encapsulated API can get injected into the virus particle.
Cutting to the chase, Dr. Diwan is the inventor of the nanomaterial that destroys viruses and we are the shareholders of the company that has exclusive rights to develop and market the technology. Dr. Diwan is talking in Chicago on Wednesday to update NNVC's pipeline.....and rapid drug development platform.
We know that there are multiple ongoing testing protocols across a wide selection of targeted viruses and being performed by private labs, big pharma, educational institutions, the CDC and the NIH. What we don't know yet is how well those tests are going and what if any findings are imminent.
What are the chances that Dr Diwan's scheduled appearance has some very good news attached to it?
This may end up being a non-event with no significant news coming out of it. Or it might be the polar opposite, with ground-breaking news making headlines across the medical universe. My best guess? Something in-between these last two outcomes. Just where it lands on the continuum between the two, that is what speculation is all about.
A
Subscribe to:
Posts (Atom)